|
Market Closed -
Nasdaq
00:00:00 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 26.24 USD | +2.94% |
|
-2.31% | +14.09% |
| 02:07pm | Ultragenyx Pharmaceutical Inc. - Special Call | |
| 08-20 | Ultragenyx Pharmaceutical Receives Accelerated US FDA Approval for Genglycos | MT |
| Market Cap | 2.58B 2.21B 2.07B 1.9B 3.56B 247B 3.62B 24.38B 9.55B 124B 9.68B 9.47B 409B | P/E 2026 * |
-6.36x | P/E 2027 * | -28.4x |
|---|---|---|---|---|---|
| Enterprise Value | 2.16B 1.85B 1.73B 1.59B 2.99B 207B 3.04B 20.42B 8B 104B 8.11B 7.94B 342B | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.19x |
| Free-Float |
96.27% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | +2.94% | ||
| 1 week | -2.31% | ||
| Current month | +5.34% | ||
| 1 month | -10.38% | ||
| 3 months | +16.88% | ||
| 6 months | +20.20% | ||
| Current year | +14.09% |
| 1 week | 24.97 |  | 26.68 |
| 1 month | 24.01 | | 29.1 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 22/04/2010 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 16/10/2023 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 22/04/2010 |
Matthew Fust
BRD | Director/Board Member | 61 | 01/01/2014 |
Michael Narachi
BRD | Director/Board Member | 66 | 20/02/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/08/26 | Sell | General Counsel | -1,900 | 0.0019% | ||
| 03/08/26 | Sell | Chief Financial Officer | -4,696 | 0.0048% | ||
| 01/07/26 | Sell | Chief Financial Officer | -4,698 | 0.0048% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.94% | -2.31% | -9.89% | -25.22% | 2.58B | |
| +9.49% | +7.34% | -2.23% | -82.37% | 2.08B | |
| -0.92% | -1.22% | -12.97% | -4.61% | 354M | |
| -1.12% | -11.60% | -49.31% | - | 50.84M | |
| Average | +2.60% | -1.95% | -18.60% | -37.40% | 1.27B | |
| Weighted average by Cap. | +5.32% | +1.64% | -7.35% | -47.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 758M 651M 608M 557M 1.05B 72.5B 1.07B 7.17B 2.81B 36.36B 2.85B 2.79B 120B | 990M 849M 793M 727M 1.37B 94.6B 1.39B 9.35B 3.66B 47.44B 3.72B 3.64B 157B |
| Net income | -435M -373M -348M -320M -601M -41.58B -611M -4.11B -1.61B -20.85B -1.63B -1.6B -68.95B | -105M -89.88M -83.92M -77M -145M -10.01B -147M -990M -388M -5.02B -393M -385M -16.61B |
| Net Debt | -418M -359M -335M -307M -578M -39.99B -588M -3.95B -1.55B -20.06B -1.57B -1.54B -66.31B | -414M -355M -331M -304M -572M -39.55B -581M -3.91B -1.53B -19.84B -1.55B -1.52B -65.58B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/08/26 | $26.24 | +2.94% | 2,846,576 |
| 18/08/26 | $25.49 | -2.45% | 1,793,436 |
| 17/08/26 | $26.13 | -1.36% | 1,316,013 |
| 14/08/26 | $26.49 | +0.42% | 1,222,222 |
| 13/08/26 | $26.38 | -1.79% | 946,127 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
